IN BRIEF / Southland
Watson Pharmaceuticals Inc. said it settled a patent-infringement lawsuit with GlaxoSmithKline, which had accused it of infringing patents on the British drug maker’s Wellbutrin antidepressant.
Glaxo sued Corona-based Watson in December 1999 and February of this year for allegedly infringing its patents by seeking U.S. regulatory approval of a generic version of Wellbutrin before the patents expired.
Watson disclosed the settlement in a Securities and Exchange Commission filing. Its shares rose $1.09 to close at $61.53 on the New York Stock Exchange.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
